Adaptive Biotechnologies (NASDAQ:ADPT) Sees Large Volume Increase – Here’s Why

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares saw strong trading volume on Wednesday . 3,589,028 shares traded hands during trading, an increase of 76% from the previous session’s volume of 2,044,294 shares.The stock last traded at $17.2220 and had previously closed at $17.22.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Adaptive Biotechnologies and set a $22 price target, implying upside from recent trading levels.
• Positive Sentiment: The company said part of the convertible-note proceeds will be used for a $25 million stock repurchase and capped-call transactions, which may help offset dilution risk.
• Neutral Sentiment: The notes carry an initial conversion price of about $24.11 per share, which is well above the recent share price and suggests management is trying to limit near-term dilution.
• Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million convertible debt deal, up from $250 million, which some investors may read as a larger-than-expected financing need.
• Negative Sentiment: Insider selling also weighed on sentiment: Chief Scientific Officer Harlan S. Robins sold 106,160 shares in recent transactions, and the recent insider activity has been entirely sales.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday. TD Cowen boosted their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Guggenheim restated a “buy” rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, Morgan Stanley lowered their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Adaptive Biotechnologies Stock Up 4.6%

The business has a 50-day moving average price of $14.80 and a 200-day moving average price of $15.57. The firm has a market capitalization of $2.81 billion, a P/E ratio of -53.16 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same period last year, the business earned ($0.20) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, insider Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the sale, the insider directly owned 250,934 shares in the company, valued at approximately $4,388,835.66. The trade was a 13.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 100,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $17.37, for a total transaction of $1,737,000.00. Following the completion of the sale, the insider directly owned 1,412,058 shares in the company, valued at approximately $24,527,447.46. The trade was a 6.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 570,634 shares of company stock valued at $8,690,995 over the last quarter. 5.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in Adaptive Biotechnologies by 45.8% during the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after buying an additional 2,914 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies during the first quarter worth approximately $93,000. New York State Common Retirement Fund increased its holdings in shares of Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after buying an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Adaptive Biotechnologies by 728.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after acquiring an additional 333,379 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.